Transatlantic tensions and the R&D debate
This article was originally published in Scrip
On September 14th, Europe's Innovative Medicines Initiative, which aims to find ways of streamlining the drug development process, will hold a press conference to present its achievements to date. Approved at the end of December 2007, the IMI is a joint effort between the EU and the European industry federation EFPIA that is expected to improve the productivity of pharmaceutical and biotech R&D and give companies a keener competitive edge.
You may also be interested in...
The bedding-in period is ending for Europe’s one-year-old system for preventing the circulation of fake medicines, and the scheme is gearing up for a more fully operational stage.
EU and US regulators have opposing views when it comes to Merck's applications for a new indication and new dosing schedule for the company's successful PD-1 inhibitor Keytruda.
Regulators have pulled out all the stops in their efforts to get the Ebola vaccine to the marketing authorization stage in Africa.